Venaxis, Inc. BIOP 深 滬
等待開盤 10-24 09:30:00 美东时间
7.67
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 7.67
- 總市值 4120.03万
- 52周最高 11.17
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 3.02
- 委 比 0.00%
- 總股本 537.16万
- 歷史最高 11.17
- 量 比 0
- 振 幅 0.00%
- 歷史最低 3.02
- 每 手 1
- 風險率 0.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BioCryst Completes Sale of European ORLADEYO® (berotralstat) Business
BuyCryst Pharmaceuticals completed the sale of its European ORLADEYO business to Neopharmed Gentili for $250 million, with up to $14 million in future milestones. BioCryst will focus on U.S. sales while Neopharmed Gentili handles commercialization in Europe. The transaction boosts BioCryst's operating margin, simplifies operations, and enables debt repayment. ORLADEYO's commercial success is expected to continue globally.
10-01 11:00
BioCryst Appoints Babar Ghias Chief Financial Officer and Head of Corporate Development
BioCryst Pharmaceuticals appoints Babar Ghias as Chief Financial Officer and head of corporate development. Ghias, formerly CFO at AvenCell Therapeutics and Marathon Pharmaceuticals, brings extensive experience in deal-making and operational leadership, particularly in rare disease companies. He has raised over $1 billion in capital and successfully launched multiple biotechnology companies. Ghias is expected to support BioCryst’s growth and capi...
07-07 11:00
Connect Biopharma to Present at Two Upcoming Investor Conferences in June
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company focused on improving treatments for asthma and COPD, announced that its management will participate in two upcoming conferences: the Noble Capital Markets Virtual Conference on June 4, 2025, and the Jefferies Healthcare Conference on June 5, 2025. The company is advancing rademikibart, a next-generation anti-IL-4Rα antibody showing strong efficacy and safety in Phase 2...
05-28 13:00
一周医药速览（11.4-11.8）
默沙东：预计未来五年将向中国引入40多项新产品和新适应证 本届进博会上，默沙东集中展示在中国境内已获批的近30种药物和疫苗，覆盖肿瘤、糖尿病、抗感染、罕见病、麻...
2024-11-08 17:30
康拓医疗(688314.SH)：已着手展开PEEK骨板在美国本土化生产的筹建工作
来源：格隆汇 格隆汇5月17日丨康拓医疗(688314.SH)于2023年5月16日下午15:00-17:00召开业绩说明会，问答环节中，就“海外业务什么时候...
2023-05-17 16:10
欧康维视生物-B(01477.HK)：营业亏损持续收窄 眼科BIOPHARAM快速成长
投资要点 事件：近 日，公司发布2022 年半年报，报告期内，公司实现营业收入54.5百万元，同比增长162.1%；亏损192.7 百万元，相较于20...
2022-09-01 00:00
